ArticleFrontiers in neurology
Exchange-free single-pass gateway balloon-assisted neuroform atlas stenting for symptomatic high-grade intracranial atherosclerotic stenosis: clinical and angiographic outcomes.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Symptomatic high-grade intracranial atherosclerotic stenosis (sICAS) is associated with a high risk of early recurrent ischemic events despite optimized medical therapy. Conventional angioplasty-to-stent workflows typically require intracranial exchange maneuvers, which may increase procedural complexity and vessel manipulation in perforator-rich territories of the brain. We evaluated the safety and early angiographic outcomes of a standardized, exchange-free, single-pass Gateway balloon-assisted Neuroform Atlas stenting strategy. Methods: We retrospectively analyzed consecutive adults with 70-99% sICAS treated at a single center (between January 2018 and January 2025). Following controlled submaximal angioplasty using a Gateway PTA balloon, a Neuroform Atlas stent was deployed directly through the balloon catheter lumen (without microcatheter exchange). Lesion morphology was retrospectively classified according to the Mori system. The primary endpoint was technical success rate. The secondary endpoints were 30-day stroke/intracranial hemorrhage/death and in-stent restenosis (ISR) > 50% on 3-month digital subtraction angiography (DSA). Results: Fifty-seven patients (median age, 70 years; 68.4% men) were treated after neurological stabilization (median event-to-stent interval, 9 days; range, 7-15 days); 63.2% had posterior circulation targets. By Mori classification, 2 lesions (3.5%) were Type A, 18 (31.6%) Type B, and 37 (64.9%) Type C. The technical success rate was 100%. No flow-limiting dissections, perforations, distal embolizations, acute in-stent thromboses, symptomatic vasospasms, 30-day strokes, or intracranial hemorrhages occurred. The 30-day mortality rate was 1.8% (due to sepsis). Median stenosis improved from 87% pre-procedure to 21.5% post-procedure and was 30% at 3-month DSA ( Conclusion: Exchange-free Gateway-Atlas stenting appears technically feasible and was associated with a low observed 30-day neurological complication rate and meaningful luminal gain in a selected cohort of patients with medically refractory sICAS, including a large proportion of morphologically complex (Mori Type C) lesions. The observed basilar artery-predominant restenosis pattern is exploratory and hypothesis-generating, and may justify closer posterior circulation surveillance in future prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.